Syndax Pharmaceuticals, Inc. (SNDX) vs Stoke Therapeutics, Inc. (STOK)

Syndax Pharmaceuticals, Inc. and Stoke Therapeutics, Inc. are both Biotechnology companies. Syndax Pharmaceuticals, Inc. and Stoke Therapeutics, Inc. are of similar size ($1.6B and $1.6B). Syndax Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 222.3% against −86.2%. Syndax Pharmaceuticals, Inc. has the higher net margin (−87.6% vs −753.6%) and the higher return on invested capital (−247.9% vs −264.8%). Across the 17 metrics below, Syndax Pharmaceuticals, Inc. leads on 9 and Stoke Therapeutics, Inc. on 8.

Valuation

Metric SNDX STOK Biotechnology median
P/E n/m n/m 7.88
P/S 6.43 59.35 11.47
P/B 107.27 4.74 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 6.65 48.73 10.73
Earnings yield (13.79%) (13.59%) (28.84%)
Free cash flow yield (13.64%) (11.04%) (23.03%)

Profitability

Metric SNDX STOK Biotechnology median
Gross margin 95.78% 100.00% 65.16%
Operating margin (77.05%) (809.69%) 0.00%
Net margin (87.60%) (753.60%) 0.00%
Free cash flow margin (87.64%) (654.92%) 0.00%
Return on equity (255.93%) (61.10%) (57.72%)
Return on assets (33.97%) (53.41%) (49.22%)
Return on invested capital (247.93%) (264.77%) 0.00%

Growth

Metric SNDX STOK Biotechnology median
Revenue growth (TTM) 222.34% (86.20%) 5.64%
EPS growth (last fiscal year) 11.56% 92.73% —
Revenue growth, 5-year CAGR 157.68% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric SNDX STOK Biotechnology median
Debt to equity 38.95 0.00 0.00
Current ratio 6.77 7.69 4.73
Net debt to EBITDA 0.25 14.29 0.96

Dividend

Metric SNDX STOK Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric SNDX STOK Biotechnology median
Market cap 1.60b 1.63b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack